HiberCell

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, HiberCell sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

HiberCell: 11 sponsored US clinical trials, 1 recruiting.

HiberCell sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Neoplasm of Breast, with 1 trials.

Top-decile sponsor footprint

HiberCell ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

NCT06234605
TERMINATED Phase 1

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05484011
TERMINATED Phase 1

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT05121948
COMPLETED Phase 2

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

NCT05159778
COMPLETED Phase 1

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

NCT04834778
TERMINATED Phase 2

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

NCT03246685
COMPLETED Phase 2

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

NCT02981303
TERMINATED Phase 3

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

NCT01309126
COMPLETED Phase 2

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NCT00874848
COMPLETED Phase 2

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00874107
COMPLETED

Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer

NCT00912327

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 1

Therapeutic Areas

Malignant Neoplasm of Breast 1
Renal Cell Carcinoma 1
Non-Small Cell Lung Cancer 1

What is open in the HiberCell pipeline

1 recruiting of 11 indexed (9% open); 6 completed (55%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Malignant Neoplasm of Breast (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

HiberCell: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

HiberCell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share HiberCellAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityGenfit
HiberCell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

HiberCell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this HiberCell page

11 registered trials is a research-attention snapshot, not an endorsement of HiberCell or any single study.

  • 1 of HiberCell's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Malignant Neoplasm of Breast is the condition HiberCell studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Neoplasm of Breast trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

HiberCell pipeline card: 11 registered trials from official public datasets.Report a data error.